Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4- methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 902-907

  Mehta, R R ^a   Hawthorne, M E ^a   Graves, J M ^a   Mehta, R G ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

4 HPR; 4 MPR; Breast cancer; Melanoma; Metabolism; Retinoids

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; FENRETINIDE; N (4 METHOXYPHENYL)RETINAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PREVENTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG METABOLISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA; PREDICTION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DIETARY SUPPLEMENTS; FEMALE; FENRETINIDE; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032078198     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00032-X     Document Type: Article

References (27)

1. 1. Sporn MB, Newton DL. Chemoprevention of cancer by retinoids. Fed Proc 1979, 38, 2528-2534.
2. 2. Schiff LJ, Okamura WH, Dawson MI, Hobbs PD. Structure-biological relationship of new synthetic retinoid on epithelial differentiation of cultured hamster tracheas. In Dawson MI, Okamura WH, eds. Chemistry and Biology of Synthetic Retinoids. Boca Raton, FL, CRC Press, 1989, 307-363.
3. 3. Moon RC, Thompson HJ, Becci PJ, et al. N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979, 39, 1339-1346.
4. 4. Moon RC, Mehta RG, Rao KVN. Retinoids and cancer in experimental animals. In Sporn MB, Roberts AB, Goodman DS, eds. Retinoids: Biology, Chemistry and Medicine. New York, Academic Press, 1994, 573-593.
5. 5. Moon RC, Pritchard FJ, Mehta RG, Nomides CT, Thomas CF, Dinger NM. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis 1989, 10, 1645-1649.
6. 6. McCormick DL, Mehta RG, Thompson CA, Dinger N, Caldwell J, Moon RC. Enhanced inhibition of mammary carcinogenesis by combination N-(4-hydroxyphenyl)-retinamide and ovariectomy. Cancer Res 1982, 42, 508-512.
7. 7. Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 1989, 49, 4472-4476.
8. 8. Abou-Issa H, Duruibe V, Minton JP, Larroya S, Dwivedi C, Webb TE. Putative metabolites derived from dietary combinations of calcium glucarate and N[4-hydroxyphenyl]retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12,dimethylbenz(a)anthracene. Proc Natl Acad Sci USA 1989, 85, 4181-4184.
9. 9. Dowlatshahi K, Mehta RG, Thomas CF, Dinger N, Moon RC. Therapeutic effect of N(-4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea induced mammary cancer. Cancer Lett 1989,47, 187-190.
10. 10. Costa A, Malone W, Perloff M, et al. Tolerability of synthetic Fenretinide (HPR). Eur J Cancer Clin Oncol 1989, 25, 805-808.
11. 11. Formelli F, Carsana R, Clerici M, Di Mauro MG. Fenretinide in chemoprevention of cancer: pharmacological studies. In De Palo G, Sporn M, Veronesi U, eds. Progress and Perspectives in Chemoprevention of Cancer. New York, Serono Symposia Publications from Raven Press, 1992, 79, 77-87.
12. 12. Formelli F, Carsana R, Costa R. N-(4-hydroxyphenyl)retinamide (4-HPR) lowers plasma retinol levels in rats. Med Sci Res 1987, 15, 843-844.
13. 13. Hultin TA, May CM, Moon RC. N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. Drug Metab Dispos 1986, 14, 714-717.
14. 14. Mehta RG, Hultin TA, Moon RC. Metabolism of the chemopreventive retinoid N-(4-hydroxyphenyl) retinamide by mammary gland in organ culture. Biochem J 1988, 256, 579-584.
15. 15. Mehta RG, Hawthorne ME, Moon RC, Formelli F, Costa A. Distribution of Fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 1991, 27A, 138-141.
16. 16. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu J, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996, 271(37), 22441-22446.
17. 17. Sheikh MS, Shao ZM, Li XS, et al. N-[4-hydroxyphenyl]-retinamide (4-HPR-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Cardnogenesis 1995, 16, 2477-2486.
18. 18. Feucht KA, Walker MJ, Das Gupta TK, Beattie CW. Effects of 17β estradiol on the growth of estrogen receptor positive human melanoma in vitro and in athymic mice. Cancer Res 1988, 48, 7093-7101.
19. 19. Rauth SR, Kichina J, Green A, Bratescu L, Das Gupta TK. Establishment of human melanoma cell line lacking p53 expression and spontaneously metastatizing in nude mice. Anticancer Res 1994, 14, 2457-2464.
20. 20. Mehta RR, Bratescu L, Graves JM, et al. Human breast carcinoma cell lines ultrastructural genotypic and immunocytochemical characterization. Anticancer Res 1992, 12, 683-692.
21. 21. Hultin TA, Mehta RG, Moon RC. A simple high-pressure liquid chromatographic method for the separation of retinoids including N-(4-hydroxyphenyl)-all-trans-retinamide. J Chromatogr 1985, 341, 187-191.
22. 22. Cobleigh MA, Dowlatshahi K, Deutsh TA, et al. Phase I/II trial of tamoxifen with or without Fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 1993, 11, 474-477.
23. 23. Mehta RG, Moon RC. Can maturation be induced in breast cancer. In Stoll BA, ed. Breast Cancer: Treatment and Prognosis. Oxford, Blackwell, 1986, 300-311.
24. 24. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993, 53, 6036-6041.
25. 25. Matsushina Y, Kawach K, Tanaka H, Kegeticca H, Hajshimota Y. Differentiation inducing activity of retinoids and their isomers and their oxidized analogs on human promyelocytic leukemia in HL-60 cells. Biochem Biophys Acta 1992, 189, 1136-1146.
26. 26. Dipietrantonio A, Hsich TC, Wu JM. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth induction of differentiation, and changes in P34cdc2, bcl-2 and actin expression in human promyelocytic HL60 leukemia cells. Biochem Biophys Res Comm 1996, 224, 837-842.
27. 27. Torisi R, Pensa F, Fontana V, Costa A, Decensi A. The metabolite N-4-methoxyphenyl retinamide is a major determinant of Fenretinide induced decline of plasma insulin like growth factor-1. Eur J Cancer 1995, 31A, 420-421.